Research programme: diagnostic and therapeutic drug discovery - Berg Pharma/Icahn School of Medicine at Mount Sinai
Latest Information Update: 16 Oct 2013
At a glance
- Originator Berg Pharma; Icahn School of Medicine at Mount Sinai
- Class Diagnostic agents
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; CNS disorders; Endocrine disorders
Most Recent Events
- 10 Oct 2013 Early research in Cancer, CNS disorders and endocrine disorders (diagnosis) in USA (unspecified route)
- 10 Oct 2013 Early research in Cancer, CNS disorders and endocrine disorders in USA (unspecified route)